The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study
    Russo, Francesco
    Linsalata, Michele
    Clemente, Caterina
    D'Attoma, Benedetta
    Orlando, Antonella
    Campanella, Giovanna
    Giotta, Francesco
    Riezzo, Giuseppe
    BMC CANCER, 2013, 13
  • [2] Gut Peptide Profile and Chemotherapy-associated Dyspepsia Syndrome in Patients with Breast Cancer Undergoing FEC60 Chemotherapy
    Riezzo, Giuseppe
    Clemente, Caterina
    Linsalata, Michele
    D'Attoma, Benedetta
    Orlando, Antonella
    Campanella, Giovanna
    Giotta, Francesco
    Russo, Francesco
    ANTICANCER RESEARCH, 2013, 33 (11) : 4951 - 4957
  • [3] Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy
    Kailajärvi, MEH
    Salminen, EK
    Paija, OMM
    Virtanen, AM
    Leino, AE
    Irjala, KA
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1271 - 1274
  • [4] Clinical Comparison on the Safety and Efficacy of Fluorouracil/Pirarubicin/Cyclophosphamide (FPC) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as Postoperative Adjuvant Chemotherapy in Breast Cancer
    Li, Ying
    Tang, Jin-Hai
    Huang, Xin-En
    Li, Chen-guang
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (07) : 1795 - 1798
  • [5] Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
    Kluger, N.
    Jacot, W.
    Frouin, E.
    Rigau, V.
    Poujol, S.
    Dereure, O.
    Guillot, B.
    Romieu, G.
    Bessis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2879 - 2884
  • [6] FAC (FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE) AS 2ND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER PROGRESSING UNDER FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) CHEMOTHERAPY
    CATIMEL, G
    CHAUVIN, F
    GUASTALLA, JP
    REBATTU, P
    BIRON, P
    CLAVEL, M
    ANNALS OF ONCOLOGY, 1994, 5 (01) : 95 - 97
  • [7] A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer
    Erman, M
    Baltali, E
    Karaoglu, A
    Abali, H
    Engin, H
    Ozisik, Y
    Guler, N
    Altundag, K
    Tekuzman, G
    CANCER INVESTIGATION, 2005, 23 (03) : 215 - 221
  • [8] FEC (5-FLUOROURACIL-EPIRUBICIN-CYCLOPHOSPHAMIDE) MONTHLY VERSUS FEC WEEKLY IN METASTATIC BREAST-CANCER - 1ST RESULTS OF A RANDOMIZED TRIAL
    BLOMQVIST, C
    ELOMAA, I
    RISSANEN, P
    HIETANEN, P
    NEVASAARI, K
    HELLE, L
    ACTA ONCOLOGICA, 1992, 31 (02) : 231 - 236
  • [9] Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients
    Wang, Zhi
    Dang, Chengxue
    Zhu, Kun
    Zhang, Yong
    Chang, Dongmin
    Xia, Peng
    Song, Yongchun
    Li, Kang
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 1088 - 1092
  • [10] Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
    Wimmer, Kerstin
    Sachet, Monika
    Ramos, Cristiano
    Frantal, Sophie
    Birnleitner, Hanna
    Brostjan, Christine
    Exner, Ruth
    Filipits, Martin
    Bago-Horvath, Zsuzsanna
    Rudas, Margaretha
    Bartsch, Rupert
    Gnant, Michael
    Singer, Christian F.
    Balic, Marija
    Egle, Daniel
    Oehler, Rudolf
    Fitzal, Florian
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
12345